VIVUS Given New $14.00 Price Target at Piper Jaffray Cos. (VVUS)
Investment analysts at Piper Jaffray Cos. decreased their price target on shares of VIVUS (NASDAQ:VVUS) from $20.00 to $14.00 in a note issued to investors on Thursday, AnalystRatings.Net reports. Piper Jaffray Cos.’s target price would suggest a potential upside of 34.49% from the company’s current price.
VVUS has been the subject of a number of other recent research reports. Analysts at Lazard Capital Markets downgraded shares of VIVUS (NASDAQ:VVUS) from a “neutral” rating to a “sell” rating in a research note to investors on Wednesday, September 4th. They now have a $8.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of VIVUS (NASDAQ:VVUS) from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, September 3rd. Finally, analysts at Credit Suisse cut their price target on shares of VIVUS (NASDAQ:VVUS) from $15.00 to $14.00 in a research note to investors on Wednesday, August 7th. They now have a “neutral” rating on the stock.
Three research analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. VIVUS presently has an average rating of “Hold” and an average price target of $15.40.
Shares of VIVUS (NASDAQ:VVUS) opened at 10.41 on Thursday. VIVUS has a one year low of $9.86 and a one year high of $24.86. The stock has a 50-day moving average of $12.94 and a 200-day moving average of $12.66. The company’s market cap is $1.050 billion. VIVUS also saw unusually large options trading activity on Monday. Stock investors acquired 8,245 put options on the company. This is an increase of approximately 203% compared to the average daily volume of 2,724 put options.
VIVUS (NASDAQ:VVUS) last released its earnings data on Tuesday, August 6th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.44) by $0.11. The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $12.76 million. During the same quarter last year, the company posted ($0.24) earnings per share. On average, analysts predict that VIVUS will post $-1.97 earnings per share for the current fiscal year.
In other VIVUS news, CFO Timothy E. Morris sold 10,654 shares of VIVUS stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $11.95, for a total value of $127,315.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.